Perinatal outcomes and sinopharm BBIBP-CorV vaccination during pregnancy

BMC Pregnancy and Childbirth, Journal Year: 2024, Volume and Issue: 24(1)

Published: March 11, 2024

Abstract Background After the outbreak of COVID-19, a huge part health care services was dedicated to preventing and treating this disease. In case COVID-19 infection, severe is reported more in pregnant individuals. Afterward, Vaccination against SARS-CoV-2 became hot topic due known effects during pregnancy. individuals started August 2021 with Sinopharm vaccine Iran. The aim current study determine incidence perinatal outcomes women who were vaccinated Method This retrospective cohort included 129,488 singleton births from March 21, 2021, until 2022, Tehran, data obtained Iranian Maternal Neonatal (IMaN) Network Registry. Adverse investigated include preterm birth, extremely low birth weight, very intrauterine growth restriction, stillbirth, neonatal intensive unit admission, congenital anomaly, death 5-minute Apgar score. risk all evaluated using multiple logistic regression. analysis done STATA version 14. Results Of study, 17,485 (13.5%) (all (BBIBP-CorV)). exposure pregnancy caused significant decrease ( P =0.006, OR=0.91 [95% CI, 0.85 0.97]), =<0.001,OR=0.55 0.45 0.66]), stillbirth =<0.001, OR=0.60 0.47 0.76]). Exposure vaccination first trimester associated an increased =0.01, OR=1.27 1.04 1.55]) not other adverse study. Conclusion finding population-based indicated no outcome second third trimesters Overall lower compared unvaccinated group. Also, birth.

Language: Английский

Maternal Exposures to COVID-19 Vaccine and Adverse Birth Outcomes: National Population Study in Korea

Journal of Korean Medical Science, Journal Year: 2025, Volume and Issue: 40

Published: Jan. 1, 2025

Language: Английский